What were Gujarat Themis Biosyn Ltd's latest quarterly results?
Gujarat Themis Biosyn Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -7.7% (stable)
- Revenue Growth YoY: +7.5%
- Operating Margin: 49.0% (volatile)
Gujarat Themis Biosyn Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +24.0%WeakNew This Week
In , Gujarat Themis Biosyn Ltd (Pharma - API) is outperforming Nifty 500 with +24.0% relative strength. Fundamentals: Weak.
Gujarat Themis Biosyn Ltd Key Facts
- PE Ratio
- 90.9x
- Market Cap
- ₹4,342 Cr
- PAT Growth YoY
- -8%
- Revenue Growth YoY
- +8%
- OPM
- 49.0%
- RS vs Nifty 500
- +24.0%
PE: At PeakDanger Bubble
What's Happening
⚠️PE rising despite falling earnings — price running ahead of reality
📊Debt increased 137% YoY — leverage rising
🌐FII stake increased 1.5% this quarter
Key Numbers
PAT Growth YoY
-8%
Stable
Revenue YoY
+8%
Inflection Up
Operating Margin
49.0%
+100 bps YoY
PE Ratio
90.9
Current Price
₹398
Dividend Yield
0.17%
Fundamental Score
28/100
Weak
3Y PAT CAGR
+4%
Market Cap
4.3K Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Gujarat Themis Biosyn Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +8% | +10% | Inflection Up |
| PAT (Net Profit) | -8% | +4% | Stable |
| OPM | 49.0% | +100 bps | Volatile |
Other Top Pharma - API Stocks Beating Nifty 500
Frequently Asked Questions: Gujarat Themis Biosyn Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Gujarat Themis Biosyn Ltd's profit growing or declining?
Gujarat Themis Biosyn Ltd's profit is declining with an stable trend.
- PAT Growth YoY: -7.7% (latest quarter)
- PAT Growth QoQ: -14.3% (sequential)
- 3-Year PAT CAGR: +3.6%
- Trend: Stable — consistent growth pattern
What is Gujarat Themis Biosyn Ltd's revenue growth trend?
Gujarat Themis Biosyn Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +7.5%
- Revenue Growth QoQ: +2.4% (sequential)
- 3-Year Revenue CAGR: +9.5%
How is Gujarat Themis Biosyn Ltd's operating margin trending?
Gujarat Themis Biosyn Ltd's operating margin is volatile.
- Current OPM: 49.0%
- OPM Change YoY: +1.0% basis points
- OPM Change QoQ: 0.0% basis points
What is Gujarat Themis Biosyn Ltd's 3-year profit and revenue CAGR?
Gujarat Themis Biosyn Ltd's long-term compounding rates
- 3-Year Profit CAGR: +3.6%
- 3-Year Revenue CAGR: +9.5%
Is Gujarat Themis Biosyn Ltd's growth accelerating or decelerating?
Gujarat Themis Biosyn Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -35.0% bps
- Sequential Acceleration: -64.3% bps
What is Gujarat Themis Biosyn Ltd's trailing twelve month (TTM) performance?
Gujarat Themis Biosyn Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹47 Cr
- TTM PAT Growth: -11.3% YoY
- TTM Revenue: ₹159 Cr
- TTM Revenue Growth: +1.9% YoY
- TTM Operating Margin: 45.1%
What is Gujarat Themis Biosyn Ltd's current PE ratio?
Gujarat Themis Biosyn Ltd's current PE ratio is 90.9x.
- Current PE: 90.9x
- Market Cap: 4.3K Cr
- Dividend Yield: 0.17%
What is Gujarat Themis Biosyn Ltd's price-to-book ratio?
Gujarat Themis Biosyn Ltd's price-to-book ratio is 16.4x.
- Price-to-Book (P/B): 16.4x
- Book Value per Share: ₹24
- Current Price: ₹398
Is Gujarat Themis Biosyn Ltd a fundamentally strong company?
Gujarat Themis Biosyn Ltd is rated Weak with a fundamental score of 28.22/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +7.5% (10% weight)
- PAT Growth YoY: -7.7% (10% weight)
- PAT Growth QoQ: -14.3% (10% weight)
- Margins stable (10% weight)
Is Gujarat Themis Biosyn Ltd debt free?
Gujarat Themis Biosyn Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹71 Cr
What is Gujarat Themis Biosyn Ltd's return on equity (ROE) and ROCE?
Gujarat Themis Biosyn Ltd's return ratios over recent years
- FY2023: ROCE 61.0%
- FY2024: ROCE 45.0%
- FY2025: ROCE 27.0%
Is Gujarat Themis Biosyn Ltd's cash flow positive?
Gujarat Themis Biosyn Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹91 Cr
- Free Cash Flow (FCF): ₹-21 Cr
- CFO/PAT Ratio: 186% (strong cash conversion)
What is Gujarat Themis Biosyn Ltd's dividend yield?
Gujarat Themis Biosyn Ltd's current dividend yield is 0.17%.
- Dividend Yield: 0.17%
- Current Price: ₹398
Who holds Gujarat Themis Biosyn Ltd shares — promoters, FII, DII?
Gujarat Themis Biosyn Ltd's shareholding pattern (Mar 2026)
- Promoters: 70.9%
- FII (Foreign): 1.8%
- DII (Domestic): 1.2%
- Public: 26.1%
Is promoter holding increasing or decreasing in Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 70.9% (Mar 2026)
- Previous Quarter: 70.9% (Dec 2025)
- Change: -0.01% (decreasing — worth monitoring)
How long has Gujarat Themis Biosyn Ltd been outperforming Nifty 500?
Gujarat Themis Biosyn Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Gujarat Themis Biosyn Ltd a new momentum entry or an established outperformer?
Gujarat Themis Biosyn Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Gujarat Themis Biosyn Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Gujarat Themis Biosyn Ltd may be worth studying
- Cash flow is positive — CFO ₹91 Cr
What is the investment thesis for Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd investment thesis summary:
What is the future outlook for Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: turning around (inflection up)
- Margin Trend: volatile
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.